Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A little action today, new patent or news tomorrow???
Leaves more time to have the run up to earnings phase. :)
One thing you can say for sure is that $BBRY does not self promote themselves very much or have a good marketing plan. Might be by design, but an interesting strategy to say the least. Found this today which was a good read that sums it up...
http://www.marketwatch.com/story/blackberry-is-back-but-do-investors-know-it-2015-11-12
Getting closer with the $BBRY Priv
https://www.att.com/cellphones/blackberry/priv.html#sku=sku7760482
Not enough to fire up the early morning crowd I guess. :(
News out and sounds positive.
down to a wait for the next flash pop and sell again. Got burned on the buy and hold theory. Look at the past 1 year chart and decide for yourself.
No problem, happy to help. Shows nothing new as of today in approved.
New patents are posted on Tuesday and this should get all the patents with CERES in them as a start.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=ceres&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT
This news could help...
http://www.bloomberg.com/news/articles/2015-10-09/astrazeneca-temporarily-halts-cancer-drug-combination-studies?cmpid=yhoo
AstraZeneca Plc said it temporarily halted two trials combining cancer drugs due to reports of lung disease.
The company stopped tests that combined its AZD9291 compound with durvalumab to treat patients with advanced non-small cell lung cancer after an increase in the incidence of interstitial lung disease-like reports, spokeswoman Esra Erkal-Paler said by e-mail, confirming a note to investors from Goldman Sachs Group Inc.
Patients enrolled in the trials, dubbed Tatton and Caural, will be given updated consent forms so they understand the new information and make a decision on whether to continue participating in the trials, she said. Tatton is an early-stage trial, while Caural is a late-stage test combining the two drugs.
AstraZeneca submitted lung cancer drug AZD9291 to U.S. regulators in June for approval. The company last year estimated peak annual sales of $3 billion for the drug.
The news may limit Astra’s ability to combine AZD9291 with other drugs and benefit U.S. rival Clovis Oncology Inc., which is developing a competing drug called rociletinib, Terence Flynn, an analyst at Goldman Sachs, said in the note.
Shares of AstraZeneca dropped 0.2 percent to 4,150.50 pence as of 9:35 a.m. in London trading.
Any credibility to this?
http://venezuelanalysis.com/news/11522
Santa Elena, September 23rd, 2015. (venezuelanalysis.com) –Venezuelan Foreign Minister Delcy Rodriguez said Saturday evening that Saudi King Salman and President Nicolas Maduro had spoken on the phone and reached an understanding concerning oil cooperation.
"Both heads of state agreed to deploy joint efforts to recover the stability of the oil market and strengthen OPEC," Rodriguez said on Twitter.
Maduro has lobbied for months for an emergency meeting of the Organization of Petroleum Exporting Countries (OPEC) and coordination with non-OPEC oil producers to cut production in order to stem the downward trend in oil prices, which last month reached a six-year low.
Venezuelan crude now hovers just above $40 a barrel which, in stark contrast to last year’s $100 barrel, has played a major role in the country’s current economic strife.
The South American nation relies on oil for 97 percent of its foreign income.
Despite Rodriguez’s affirmations, Saudi Arabian representatives have previously said they see no need to interfere in the oil market, or call an emergency summit.
Indeed, analysts have pointed to the Gulf nation, the largest oil exporter in the world, as a key player in a game of strategy that has seen a decline in prices as nations vie for market share.
In response, Venezuela recently tried a different tactic. Rather than aiming for production cuts, government officials alluded last week to a proposal that would focus on sustaining a price floor based on quarterly analyses.
“The minimum, minimum price should be $70,” Maduro said during a televised speech last week. “Oil at $70 a barrel guarantees investments needed for global energy and economic stability.”
"This is a win-win proposal. Nobody wins with unstable prices,” the Venezuelan leader added.
Venezuelan Oil Minister Eulogio Del Pino has emphasized a coordinated effort as necessary, not only for the good of Venezuela’s economy, but for other oil-producing nations as well.
“Our average production cost is less than $10 per barrel and if we go to a price war, it is obvious that the low-cost countries will have certain levels of gains, but we recognize that low-cost producers can’t fill the void in worldwide production of oil,” said Del Pino, who is also president of the state oil company PDVSA.
Early in September, President Maduro met with Russian leader Vladimir Putin in Beijing, who agreed to "several initiatives" to balance the market, Venezuelan state media reported.
However, Kremlin spokesperson Dmitry Peskov said at the time “no concrete steps were taken,” and Russian Energy Minister Alexander Novak said last week that Moscow had rejected Venezuela’s request to cut output.
The Venezuelan President announced last week forthcoming plans to travel East to lobby for an urgent OPEC summit.
Currently the Head of State is touring the Caribbean, reaffirming political and economic ties in countries such as Trinidad and St. Kitts & Nevis.
No clue at all anymore. At one point I actually thought they were making a difference and now is it all about the price and volume. If they are running it up before hours then sell into it if you ask me, but then again what do I know.
From today's S-3 breaking the silence here on the board....
This prospectus relates to the resale by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” from time to time, of up to 2,398,859 shares of our Common Stock, par value $0.01 per share, issuable upon exercise of the Warrants. As of the date of this prospectus, none of the Warrants are exercisable by the selling stockholders. The July 2015 Warrants will become exercisable beginning on January 30, 2016, and the August 2015 Warrants will become exercisable beginning on February 26, 2016. We are not selling any shares of Common Stock under this prospectus and will not receive any proceeds from the sale of shares of Common Stock by the selling stockholders.
This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (“SEC”) utilizing a “shelf” registration process. It omits some of the information contained in the registration statement and reference is made to the registration statement for further information with regard to us and the securities being offered by the selling stockholders. Any statement contained in this prospectus concerning the provisions of any document filed as an exhibit to the registration statement or otherwise filed with the SEC is not necessarily complete, and in each instance, reference is made to the copy of the document filed.
You should read this prospectus, any documents that we incorporate by reference in this prospectus and the additional information described below under “Where You Can Find More Information” and “Information Incorporated By Reference” before making an investment decision. You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
You should not assume that the information in this prospectus or any documents we incorporate by reference herein or therein is accurate as of any date other than the date on the front of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates.
Unless otherwise indicated in this prospectus, “Ceres”, “our company”, “the Company”, “we”, “us” and “our” refer to Ceres, Inc. and our subsidiaries, Ceres Sementes do Brasil Ltda., Ceres Agrotechnologies Intl LLC and CS Semillas de México, S. de L. de C.V.. This document may also contain references to trademarks and service marks of other companies that are the property of their respective owners.
Interesting how another of the top dogs sold off before the news. Coincidence?
Tetraphase Pharmaceuticals Inc
COO John Craig Thompson disposed of 10,000 Tetraphase Pharmaceuticals shares (96% of total stake), valued at $440,800, in a transaction dated September 9. The shares were sold via automatic sale program. Thompson now holds 343 of the company’s shares that are valued at $2,909.
Agree, as long as they they don't stop writing the book there are opportunities.
Coincidence that the boss sold many of his shares in the past week? With the price drop continuing maybe the story has a few more chapters to be told.
they run it like a penny from what I have learned over the years, sad
Ceres Updates U.S. Forage Sorghum Plantings
- Higher than expected plantings of products provide a larger base for expansion
- Early performance results this season have been favorable
THOUSAND OAKS, Calif. – September 10, 2015 – Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology company, today revised upwards the number of acres planted with its improved forage sorghum hybrids. The company, which closed its fiscal year on August 31, indicated that the higher than expected demand from growers and dairies could favorably impact the adoption rate of its Blade brand forage sorghum products next season.
For the 2015 growing season in North America, the company sold more than 4,000 acres of its Blade brand seed products for commercial evaluations, compared to approximately 3,000 acres previously estimated in July and 600 acres planted the previous season. As an outlet for previous generations of products in its portfolio, the company also introduced generic seed for certain market segments. Plantings of generic seed are expected to cover several thousand additional acres this season.
Growers and distributors have reported favorable early performance results to date, including improved stands and growth rates compared to competitor products. Customers are expected to have final metrics, including yields per acre and feed quality, for Ceres’ forage sorghum hybrids by the end of the calendar year when the season is complete. Planting decisions for the 2016 season typically begin at that time. Growers typically increase plantings of new products once they confirm performance under their growing practices.
Ceres President and CEO Richard Hamilton said that the company intends to establish its brand and market presence through improved conventional hybrids ahead of the introduction of its traits, which are currently being evaluating in the field and greenhouse.
“We have a compelling opportunity to combine the natural drought tolerance of forage sorghum with improved yield and quality traits. By improving sorghum, we believe we can both increase our market share in forage sorghum and also expand the size of the overall forage sorghum market,” said Hamilton.
He noted that the company’s strategy to refocus on markets being fueled by growing global prosperity has proceeded well. “With oil falling toward $40 a barrel and high quality hay reaching as much as $400 a ton, we believe our shift away from bioenergy is being validated, and we are positioning ourselves now to grow along with global prosperity.”
Last season, the company’s Blade forage sorghum hybrids performed well in numerous commercial and multi-hybrid field trials in the United States and demonstrated a number of favorable attributes for forage feed, including lower water and nitrogen fertilizer requirements than other crops. In general, forage sorghum requires 60% less water than alfalfa hay and 20% less water than silage corn, which are both commonly used as livestock feed. Sorghum is also more resilient to periods of drought during the growing season.
Ceres’ technology has been the focus of a number of patent awards recently. In August, the company was awarded a U.S. patent for its iCODE multi-gene trait development system. iCODE was developed to rapidly create, evaluate and select optimal combinations of genes and their control components for next-generation biotechnology traits in crops such as corn and soybean. The company is currently in discussions with institutions and companies to establish best practices for evaluating the technology for larger scale deployment. Early this year, Ceres also received a patent award for an innovation in soybean related to plant processes that are the target of a class of commercial herbicides. Ceres plans to offer other seed companies a commercial license to its innovations, including an opportunity for exclusivity in certain crops.
It would be nice if the company posts a response and advises the true status of the trials and testing and next steps as they said they would
More like Bio-Shock.
I wonder if the ETF with over 3% of the stock in their holdings was one of the major contributing factors in the selling.
https://www.etfchannel.com/symbol/xph/
No doubt, no mercy anymore for any speed bump. Curious to see their update and where this is in a week.
Same here, I would think slightly oversold.
If there is ever an upside it generally only happens for minutes, not days weeks or years.
Good technology for a good company, so to say. I think so too and being platform agnostic at one point will definitely will help.
News for BBRY ...Buys Good Technology
By acquiring Good, BlackBerry (NASDAQ:BBRY) will better solve one of the biggest struggles for CIOs today, especially those in regulated industries: securely managing devices across any platform," says CEO John Chen.
The $425M cash deal is expected to close near the end of 2016 FQ3, and should be accretive to earnings and cash flow within the first year after closing. BlackBerry expects to realize about $160M in GAAP revenue in year one from Good.
A conference call is set for 8:30 ET.
Not your typical run on news......hmmmm
No doubt, lets see how many trade hands today. :)
You may get your chance today....News and pre-market is active $1.32
Bummer, one thing to keep an eye out for is the flash pop that they seem to manage every so often like the last one. Maybe you get lucky and can get out if that is what you want to do. GLTA
Am I missing something or are they stamping out some more shares while they still have some to go on the 1st S-3?
http://ih.advfn.com/p.php?pid=nmona&article=68369457&symbol=CERE
more like hibernation
Up, up and away goes the float.
As of August 12, 2015, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $11,201,755, based on 7,232,222 shares of outstanding common stock, of which approximately 5,437,745 shares were held by non-affiliates, and a per share price of $2.06 per share, which was the last reported sale price of our common stock on The Nasdaq Capital Market on August 12, 2015. The aggregate market value of our common stock sold pursuant to General Instruction I.B.6. of Form S-3 during the prior 12 calendar month period that ends on and includes the date of this prospectus supplement is $3,505,343.16.
They like to waterboard the shareholders with the drip, drip, drip of the S-3 and its dilution.
No kidding, plus you have to spot on when it happens and most of it hit before hours to boot. Swimming with the sharks is not for me and sitting on the sidelines for now.
Still more to go....float going up again
Item 8.01 Other Events.
The Company announced that on August 20, 2015 it entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,598,478 shares of common stock at a price of $1.22 per share and warrants to purchase up to 1,198,859 shares of common stock at an effective price of $0.09375 per warrant with an exercise price of $1.22 per share (the “Offering”). The warrants will be exercisable six months following the closing date and will expire five years from the date they become exercisable.
The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-204024), which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 17, 2015. The warrants and shares issuable upon exercise of the warrants were offered in a concurrent private placement and have not been registered under the Securities Act of 1933, as amended. Ceres has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the warrants.
The closing of the Offering is expected to take place on or about August 26, 2015, subject to the satisfaction of customary closing conditions.
On August 21, 2015, the Company issued a press release in connection with the Offering titled “Ceres Announces Pricing of $2.1 Million At-the-Market Registered Direct Offering and Private Placement.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
So the bigger question is when it gets under a buck again will the cycle repeat or are they done? So far it is trending down and it probably is not related to China.
I figured that it may be ICODE but it was more important for the company to allow the players to all line up before releasing it if you ask me. They waited over a month on the last one on soybeans to release it and that was the last time the volume went thru the roof. Shifty way to run a company IMO. The key will be to wait and see if they release some S-3 news to make it fall like the last time and then load up and do the same. There are traders and hedge funds here that are way better at it than me and I am out on the sidelines.
and unless they announce the s-3 closed I figure there is still 7M ish give or take left on it unless I am missing something.
That's a shocker. There should be some news soon on another deal to dole out some S-3 shares to some "investors". That's what sent it overnight from 2 to 1 last time. At least that is the history unfortunately.